TG Therapeutics (NASDAQ:TGTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report sent to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $49.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on TGTX. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a neutral rating in a research report on Wednesday, August 7th. B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a buy rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics presently has an average rating of Moderate Buy and a consensus target price of $31.83.

TG Therapeutics Stock Performance

TGTX opened at $24.65 on Wednesday. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $26.41. The stock has a market cap of $3.81 billion, a P/E ratio of 107.17 and a beta of 2.21. The stock’s 50 day simple moving average is $22.08 and its 200 day simple moving average is $18.35. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. TG Therapeutics’s revenue was up 357.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.34) earnings per share. As a group, equities analysts anticipate that TG Therapeutics will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds have recently modified their holdings of TGTX. Pingora Partners LLC purchased a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $27,000. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the 2nd quarter valued at $35,000. DekaBank Deutsche Girozentrale purchased a new position in shares of TG Therapeutics during the 1st quarter worth $58,000. Lazard Asset Management LLC acquired a new stake in shares of TG Therapeutics during the first quarter worth $91,000. Finally, nVerses Capital LLC grew its position in shares of TG Therapeutics by 34.9% in the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,500 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.